The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer ...

Patients with cancer cachexia and an elevated level of growth differentiation factor 15 (GDF-15) achieved significant ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary ...

Pfizer Inc. (PFE) said Saturday that its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation ...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see ...

Pfizer's (PFE) experimental therapy for cancer related weight loss, ponsegromab, meets the primary endpoint in Phase 2 trial.

The Phase II study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its ...

Pharma giant Pfizer said that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results ...

Pfizer Inc. (NYSE: PFE) experienced a notable uptick in its stock price during Monday’s trading session, climbing by +2.12% to reach $29.89 at 11:10 AM EDT. This positive movement comes in the wake of ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...